Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Promoter methylation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methylation (or hypermethylation) of the MGMT gene promoter down-regulates or inactivates the normal DNA-repair function of the MGMT enzyme, which can make tumors more susceptible to radiation or alkylating agent-based therapy. Testing is particularly useful in gliomas.
Method for detection of promoter methylation status
InactiveUS7358048B2Precise “ molecular signature ”Accurately methylation statusMicrobiological testing/measurementFermentationCapillary electrophoresisElectrophoresis
Owner:CORNELL RES FOUNDATION INC
Method for detection of promoter methylation status
InactiveUS20050227265A1Precise “ molecular signature ”Accurately methylation statusMicrobiological testing/measurementFermentationCapillary electrophoresisElectrophoresis
The present invention relates to the detection of promoter methylation status using a combination of either modification of methylated DNA or restriction endonuclease digestion, multiplex polymerase chain reaction, ligase detection reaction, and a universal array or capillary electrophoresis detection.
Owner:CORNELL RES FOUNDATION INC
Skin Sampling Kit Which Stores Nucleic Acids In Stable Status, Genetic Test Methods By Using The Kit And Their Practical Application
InactiveUS20110033842A1Easily and stably acquiredAccurate conditionBioreactor/fermenter combinationsBiological substance pretreatmentsGenomicsSkin test results
The present invention relates to a new skin gene card for genetic test, a method for acquiring DNA and RNA and performing various genetic tests using the same, and practical applications thereof. More specifically, the inventors of the present invention have developed a skin gene card capable of acquiring samples from human skin, hair or mucosa simply, safely and quickly and enabling stable long-term storage and transport of DNA and RNA included in the acquired sample at room temperature. Various genetic tests may performed using the acquired DNA and RNA, including polymerase chain reaction (PCR), reverse transcription (RT)-PCR, real-time PCR, sequencing, hybridization, DNA chip analysis, single-nucleotide polymorphism (SNP) assay, gene mutation assay, promoter methylation assay, gene expression assay, etc. The genetic skin test result may be utilized for disease prognosis, nutrigenomic test, pharmacogenomic test, forensic test such as personal identification, diagnosis of genetic diseases, diagnosis of skin diseases, or the like. In addition, through an objective evaluation of the skin or hair condition, a personalized cosmetic and skin care system may be established for practical application in beauty care, cosmetology, dermatology, and clinical practice.
Owner:GOODGENE
Method and assay for early diagnosis of prostate cancer
InactiveUS20060246496A1Microbiological testing/measurementBiological material analysisDiagnosis earlyProstate cancer
Owner:UNIV OF MARYLAND
Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.
Owner:GENOMICTREE
Application of LRRC4 gene promoter zone methylation detection to glioma diagnosis and detection system
InactiveCN101298629ASimple and fast operationImprove stabilityMicrobiological testing/measurementDiagnosis earlyA-DNA
The invention discloses an application of the LRRC4 gene promoter methylation detection to the glioma diagnosis and a detecting system thereof. The brain tissue specificity expressive gene LRRC4 is the glioma specificity methylate alienation gene, thereby indicating that the LRRC4 gene promoter methylation detection can be applied to the early period diagnosis of the glioma and the LRRC4 gene promoter methylation detecting system can be prepared by comprising a DNA bisulfite modification kit and an LRRC4 promoter methylation specificity PCR augmentation kit. The detecting system detects the specificity of the plasma LRRC4 promoter methylation state up to 92 percent, has high sensitivity, and can detect the plasma LRRC4 promoter methylation state of people quantificationally, thereby diagnosing the glioma of the patient rapidly without wound in the early time.
Owner:CENT SOUTH UNIV
Kit for detecting methylation level of lung cancer associated SHOX2 gene promoter region
ActiveCN105316421AHigh sensitivityImprove throughputMicrobiological testing/measurementReference genesForward primer
The invention discloses a Kit for detecting the methylation level of a lung cancer associated SHOX2 gene promoter region, which comprises a target gene primer pair, a reference gene primer pair, Taqman probes, and blocking agents, wherein the Taqman probe is used for detecting target genes and reference genes, and the blocking agent has a blocking effect. The target gene primer pair comprises a target gene forward primer shown in a sequence SEQ ID NO.1 and a target gene reverse primer shown in a sequence SEQ ID NO.2; and the reference gene primer pair comprises a reference gene forward primer shown in a sequence SEQ ID NO.3 and a reference gene reverse primer shown in a sequence SEQ ID NO.4. The target gene Taqman probe for detecting is shown in a sequence SEQ ID NO.5, and the reference gene Taqman probe is shown in a sequence SEQ ID NO.6. The blocking agents are shown in a sequence SEQ ID NO.7 and a sequence SEQ ID NO.8.
Owner:湖南宏雅基因技术有限公司
Methods and compositions for detecting cancers associated with methylation of hMLH1 promoter DNA
Methods are provided for detection of cancers associated with methylation of hMLH1 promoter DNA in a subject. The method comprise assaying for the presence of methylated hMLH1 promoter DNA in a bodily fluid from a subject. In one embodiment, the method comprises reacting DNA from the sample with a chemical compound that converts non-methylated cytosine bases but not methylated cytosine bases, to a different nucleotide base. The compound-converted DNA is then amplified using a methylation-sensitive polymerase chain reaction (MSP) employing primers that amplify the compound-converted DNA template. The present invention also provides nucleotide primer sequences for use in the methylation-sensitive PCR assay.
Owner:CASE WESTERN RESERVE UNIV
Use of lecithin:retinol acyl transferase gene promoter methylation in evaluating the cancer state of subject
The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.
Owner:RUTGERS THE STATE UNIV +2
Method and assay for early diagnosis of prostate cancer
A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of promoter methylation of gal-3, optionally in combination with the quantification of the level of GSTP1 promoter methylation, where the method and assay are non-invasive to a subject and can detect any of Stages I-IV prostate cancer.
Owner:UNIV OF MARYLAND
New skin sampling kit which stores nucleic acids in stable status, genetic test methods by using the kit and their practical application
InactiveCN101990578AEx situ and stable acquisitionAccurate evaluationMicrobiological testing/measurementSurgical needlesStable statusSkin test results
Owner:GOODGENE
Lifetime predicting system for patient with glioblastoma multiforme
ActiveCN106874647APrediction is accurateShorten the timeMedical simulationHealth-index calculationGlioblastomaTotal risk
The invention discloses a lifetime predicting system for a patient with glioblastoma multiforme. The predicting system comprises an input module, an analyzing module and an output module; the analyzing module can establish a survival probability alignment chart based on variables input by a variable input module and calculate the total risk score, wherein the total risk score is a cumulative sum of Karnofsky performance score, tumour excision degree, MGMT gene promoter methylating state, IDH gene state and risk score of a temozolomide treatment policy; and the input module calculates a lifetime predicted value of the patient with glioblastoma multiforme according to the total risk score; the output module is used for outputting the lifetime predicted value of the patient with glioblastoma multiforme. The lifetime predicting system for the patient with glioblastoma multiforme, disclosed by the invention, integrates variables which are easily acquired clinically, and the five variables are input to quickly and accurately acquire a predicted result of the lifetime of the patient with glioblastoma multiforme, so that the time and vigor of a user are saved.
Owner:吴安华
Quantitative detection method and reagent kit of GSTP1 (Glutathione S-Transferase P1) methylation for predicting hepatic failure prognosis
InactiveCN103805699AGuaranteed specificityStrong specificityMicrobiological testing/measurementFluorescence/phosphorescenceReference genesGenomic DNA
The invention provides a quantitative detection method and a reagent kit GSTP1 (Glutathione S-Transferase P1) methylation for predicting hepatic failure prognosis. The invention relates to quantitative detection for gene methylation, and in particular relates to a quantitative detection method and a reagent kit f GSTP1 (Glutathione S-Transferase P1) methylation for predicting hepatic failure prognosis. The reagent kit contains a reagent for extracting genomic DNA (Deoxyribonucleic Acid), a reagent for modifying the genomic DNA, a 5x premixing PCR (Polymerase Chain Reaction) system, a standard substance, positive and negative control, a methylation-specific primer pair aiming at a target gene GSTP1 promoter, a specific primer pair of a reference gene ALU-C4, and a corresponding Taqman fluorescent probe. By extracting peripheral blood genomic DNA and carrying out real-time fluorescence quantitative PCR, a quantitative value of the gene GSTP1 methylation is obtained through calculation. The reagent kit provided by the invention can help doctors to determine the pathogenetic condition and prognosis of hepatic failure patients so as to make effective treatment plans.
Owner:SHANDONG UNIV QILU HOSPITAL
Biomarker and method for detecting HBV related hepatocellular carcinoma
PendingCN105755150AReduce sensitivityHigh diagnostic efficiencyMicrobiological testing/measurementDNA/RNA fragmentationInsulin-like growth factor bindingAlpha-fetoprotein
The invention relates to the field of medical science, and provides a biomarker for hepatocellular carcinoma related detection, particularly a biomarker for detecting HBV related hepatocellular carcinoma. The biomarker comprises an insulin-like growth factor binding protein 7 (IGFBP7) and an alpha fetoprotein (AFP). A method for detecting hepatocellular carcinoma, based on the biomarker namely the IGFBP7 and the AFP, comprises a step of carrying out judgement by measuring a marker IGFBP7 gene promotor methylation level and detecting the sensitivity of the marker AFP for being combined with serum IGFBP7 gene promoter methylation. According to biomarker, the AFP is combined with the IGFBP7 gene promoter methylation, so that the traditional detection of single indexes is changed, and the efficiency of HCC diagnosis is increased.
Owner:SHANDONG UNIV QILU HOSPITAL
MGMT gene promoter methylation detecting method, sequencing data processing method and processing device
ActiveCN110211633AImprove accuracyImprove throughputMicrobiological testing/measurementProteomicsReference genome sequencePromoter methylation
The invention provides an MGMT gene promoter methylation detecting method, a sequencing data processing method and a processing device. The processing method comprises the steps of acquiring methylation sequencing data from the MGMT gene promoter, wherein the methylation sequencing data are a double-end sequencing sequence; comparing the methylation sequencing data with a human reference genome sequence for obtaining a comparing result, wherein a comparing result comprises a first-end first matching area, a first-end second matching area, a second-end first matching area and a second-end second matching area, the first-end second matching area is overlapped with the second-end second matching area; eliminating the first-end second matching area or the second-end second matching area in a comparing result for obtaining to-be-analyzed data; and performing methylation site identification on to-be-analyzed data for obtaining a methylation result of the MGMT gene promoter. The methylation site which is detected by the processing method has relatively high accuracy and relatively high flux, thereby facilitating evaluation of methylation level in an integral manner.
Owner:GENECAST WUXI PRECISION MEDICAL DIGNOSTIC LAB
Kit and primer pair group for detecting expression of cytosine deaminase and molecular genes related to cytosine deaminase in free DNA (deoxyribonucleic acid) in peripheral blood
ActiveCN105177141AIncreased sensitivityHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationCytosine deaminaseTreatment effect
The invention discloses a kit and a primer pair group for detecting expression of cytosine deaminase (Apobec3B / C, Apobec3F / G and AID) and molecular (UNG) genes related to cytosine deaminase in free DNA (deoxyribonucleic acid) in peripheral blood. The primer pair group is shown in SEQ ID No:1-SEQ ID No:8 in a sequence table. The kit containing the primer pair group evaluates the risk of cancer incidence and the treatment effects by detecting methylation modification of Apobec3B / C, Apobec3F / G, AID and UNG gene promoters. A detection method has the characteristics of high sensitivity, specificity, directness, real-time property and stability.
Owner:欧浦德生物科技(北京)有限公司
Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.
Owner:GENOMICTREE
Method for detecting gene promoter methylation
The present invention relates to a detection method of gene promoter methylation. Said method includes the following steps: firstly, using freshly-prepared modification reagent to modify extracted DNA, after the modified DNA is passed through column, making purification and desulfurization reaction, then using absolute ethyl alcohol and salmon sperm DNA to enrich micro modified DNA, further selecting and using specific PCR GC Buffer to make multiple methylation specific PCR amplification, then adopting electrophoresis technique to analyze result.
Owner:冯景 +1
Methods and compositions for the diagnosis and treatment of cancer
ActiveUS20110201669A1Increase contrastImprove image qualityBioreactor/fermenter combinationsBiocideCancer cellReticulum cell
The present invention relates to the diagnosis and treatment of cancer, and in particular breast cancer. Specifically, in some embodiments the invention relates to methods of diagnosing cancer, and in particular breast cancer, using an antibody specific for a gene product that localizes selectively to the endoplasmic reticulum of the cancer cell(s). In some embodiments, the invention relates to methods of treating cancer, and in particular breast cancer, by administering a composition comprising an RNA interference sequence (e.g., shRNA, RNAi and / or siRNA molecule) characterized by an ability to inhibit an mRNA molecule, which mRNA molecule is encoded by the C43 gene (SEQ ID NO: 1). The invention additionally relates to methods for detecting cancer cells by detecting reduced methylation of the C43 promoter, and methods for reducing cancer metastasis by using demethylation inhibitors that result in increased methylation of the C43 promoter. The invention additionally relates to an in vitro 3-dimensional assay for detecting migrating cells, identifying test agents and / or nucleotide sequences that alter cell migration.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Diagnosis and treatment of tumor-suppressor associated disorders
InactiveUS20070072224A1Peptide/protein ingredientsMicrobiological testing/measurementAbnormal tissue growthDisease
Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE +1
Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
InactiveUS20130123116A1Microbiological testing/measurementLibrary member identificationBladder cancerOncology
Owner:GENOMICTREE
CpG retrieval of DNA from formalin-fixed pathology specimen for promoter methylation analysis
InactiveUS7125673B2Sugar derivativesMicrobiological testing/measurementPathology diagnosisOverall survival
The present invention provides a method, referred to as CpG retrieval, to overcome incomplete bisulfite modification of DNA recovered from formalin-fixed tissue samples. The method involves boiling deparaffinized tissue samples in citrate buffer, followed by DNA extraction for promoter methylation analysis. In general, the extracted DNA is further modified by sodium bisulfite and then subjected to a method of promoter methylation analysis. The present invention also reports that hypermethylation of ataxia-telangiectasia-mutated gene promoter is correlated with decreased overall survival in patient with head and neck squamous cell carcinoma.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1
Compositions and methods for detecting a neoplasia
ActiveUS20130288241A1Sugar derivativesMicrobiological testing/measurementBlood plasmaPromoter methylation
The invention provides compositions and methods for detecting a neoplasia (e.g., pancreatic cancer, lung cancer, colon cancer) in a subject sample (e.g., serum, blood, plasma, tissue). In particular embodiments, the invention provides methods for detecting BNC1 and ADAMTS1 promoter methylation in circulating DNA in serum.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.
Owner:GENOMICTREE
CpG retrieval of DNA from formalin-fixed pathology specimen for promoter methylation analysis
InactiveUS20050196769A1Reduced survivalSugar derivativesMicrobiological testing/measurementPathology diagnosisOverall survival
The present invention provides a method, referred to as CpG retrieval, to overcome incomplete bisulfite modification of DNA recovered from formalin-fixed tissue samples. The method involves boiling deparaffinized tissue samples in citrate buffer, followed by DNA extraction for promoter methylation analysis. In general, the extracted DNA is further modified by sodium bisulfite and then subjected to a method of promoter methylation analysis. The present invention also reports that hypermethylation of ataxia-telangiectasia-mutated gene promoter is correlated with decreased overall survival in patient with head and neck squamous cell carcinoma.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1
SFRP1 gene promoter methylation detection primers and detection method thereof
InactiveCN105986035AImprove accuracyIncrease abundanceMicrobiological testing/measurementDNA/RNA fragmentationSFRP1 GeneLower risk
The invention discloses SFRP1 gene promoter multi-CG-locus methylation detection primers and a detection method thereof. The method comprises the following steps: (1) forward and reverse degenerate primers SEQ NO 1 and SEQ NO 2 in the SFRP1 gene promoter region are amplified; (2) the target sequence amplified by the primers comprise at least 7 CG loci; and (3) as for the problems of severe paraffin section DNA fragmentation and low effective template concentration in the bisulfite modification saturated state, Touch-down PCR amplification and Sanger sequencing are combined to obviously enhance the detection sensitivity. The primers and method have the advantages of high specificity, high accuracy, low risk of contamination and the like and can detect multi-CG-locus methylation in the SFRP1 gene promoter region of the tumor patient surgery paraffin section; and the result can instruct the doctors to perform prognosis evaluation on related diseases.
Owner:杭州艾迪康医学检验中心有限公司
Detection method for methylation of MGMT gene promoter, and primer group
InactiveCN109837341AImprove throughputImprove featuresMicrobiological testing/measurementDNA/RNA fragmentationSemiconductor chipGene technology
The invention relates to the fields of molecular biology gene technology and medicine, and specifically discloses a detection method for methylation of an MGMT gene promoter, and a primer group. The methylation degree of a CpG island of the MGMT gene promoter is analyzed, the corresponding primer group is designed, sample genome DNA is subjected to methylation specific PCR (MSP) amplification, andan Ion Torrent semiconductor chip sequencing technology is detected. The detection method has the advantages of large flux, high specificity and sensitivity, stable results, good repeatability and fast detection speed. A fast, reliable and accurate new way is provided for detection, testing, analysis and evaluation of methylation of the MGMT gene promoter, and a theoretical basis is provided forscreening of personalized drugs for sensitive individuals.
Owner:上海联吉医学检验所有限公司
Primer probe system for SEPT9 (septin-9) gene promoter methylation detection and kit adopting primer probe system
InactiveCN105441553AImprove accuracyEnsure the quality of vulcanization modificationMicrobiological testing/measurementDNA/RNA fragmentationForward primerFluorescence
The invention relates to a primer probe system for SEPT9 (septin-9) gene promoter methylation detection and a kit adopting the primer probe system. The primer probe system comprises a primer probe set X used for determining genomic DNA quality, a primer probe set Y used for determining a methylation conversion rate and a primer probe set Z used for detecting SEPT9 gene promoter methylation conditions, wherein the primer probe set X comprises a forward primer a, a reverse primer a and a probe a; the primer probe set Y comprises a forward primer b, a reverse primer b and a probe b; the primer probe set Z comprises the forward primer b, the reverse primer b and a probe c; fluorescence report groups are arranged at 5' ends of the probe a, the probe b and the probe c, and fluorescence quenching groups are arranged at 3' ends of the probe a, the probe b, the probe c and the probe d. According to the kit, the implementing scheme is concise, and the sensitivity and the accuracy rate are high.
Owner:上海赛安生物医药科技股份有限公司
MGMT gene promoter methylation assay primer probe system and kit thereof
ActiveCN105463096AHigh sensitivityEnsure the quality of vulcanization modificationMicrobiological testing/measurementDNA/RNA fragmentationForward primerFluorescence
The invention relates to a MGMT gene promoter methylation assay primer probe system and a kit thereof. The system comprises a primer probe group X for determining the DNA quality of a genome, a primer probe group Y for determining methylation conversion ratio and a primer probe group Z for detecting the situation of MGMT gene promoter methylation, wherein the primer probe group X comprises a forward primer a, a reverse primer a and a probe a; the primer probe group Y comprises a forward primer b, a reverse primer b and a probe b; the primer probe group Z comprises a forward primer b, a reverse primer b and a probe c; the 5' terminals of the probe a, the probe b and the probe c are provided with a fluorescence reporter groups; and the 3' terminals of the probe a, the probe b and the probe c are provided with quenching fluorescence groups. The kit is concise in implementation scheme, high in sensitivity and high in accuracy.
Owner:南京申基医药科技有限公司
Method of detecting bladder urothelial carcinoma
A diagnostic method for bladder urethelial carcinoma includes obtaining an isolated nucleotide sample from a subject and detecting the promoter methylation of at least three tumor suppressor genes selected form group consisting of DAPK, RAR-beta, p14, p73, MGMT, APC, SOCS-1, BRCA-1, and FHIT.
Owner:THE CLEVELAND CLINIC FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com